|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300071375 |
|
最近更新日期: Date of Last Refreshed on: |
2023-06-09 14:31:21 |
|
注册时间: Date of Registration: |
2023-05-12 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
CT引导下经皮腰交感神经节射频/臭氧毁损术治疗难治性高血压 |
|
Public title: |
CT-guided ozone-mediated lumbar sympathetic denervation (OL-SDN) in patients with resistant hypertension (RH) |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
CT引导下经皮腰交感神经节射频/臭氧毁损术治疗难治性高血压 |
|
Scientific title: |
CT-guided ozone-mediated lumbar sympathetic denervation in patients with resistant hypertension |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李丽 |
研究负责人: |
李丽 |
|
Applicant: |
Li Li |
Study leader: |
Li Li |
|
申请注册联系人电话: Applicant telephone: |
+86 189 2890 0300 |
研究负责人电话:
Study leader's |
+86 189 2890 0300 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lilygs@126.com |
研究负责人电子邮件: Study leader's E-mail: |
lilygs@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国广东省广州市海珠区同福中路396号 |
研究负责人通讯地址: |
中国广东省广州市海珠区同福中路396号 |
|
Applicant address: |
396 Tongfu Middle Road, Haizhu District, Guangzhou City, Guangdong Province, China |
Study leader's address: |
396 Tongfu Middle Road, Haizhu District, Guangzhou City, Guangdong Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
510220 |
研究负责人邮政编码: Study leader's postcode: |
510220 |
|
申请人所在单位: |
广州市红十字会医院 |
||
|
Applicant's institution: |
Jinan University, Guangzhou Red Cross Hospital |
||
|
研究负责人所在单位: |
广州市红十字会医院 |
||
|
Affiliation of the Leader: |
Jinan University, Guangzhou Red Cross Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
穗红医院伦审2022-145-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广州市红十字会医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethic committee of Guangzhou Red Cross Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-07-05 00:00:00 | ||
|
伦理委员会联系人: |
邝莹 |
||
|
Contact Name of the ethic committee: |
Ying Kuang |
||
|
伦理委员会联系地址: |
中国广东省广州市海珠区同福中路396号 |
||
|
Contact Address of the ethic committee: |
Jinan University, Guangzhou Red Cross Hospital |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 6188 3974 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
广州市红十字会医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Jinan University affiliated Guangzhou Red Cross Hosptal |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广州市红十字会医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Jinan University, Guangzhou Red Cross Hospital |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
广州市科学技术局 |
||||||||||||||||||||||
|
Source(s) of funding: |
Guangzhou Science and Technology Bureau |
||||||||||||||||||||||
|
研究疾病: |
难治性高血压 |
||||||||||||||||||||||
|
Target disease: |
Resistant Hypertension |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
探索CT引导下经皮腰交感神经节射频/臭氧毁损术治疗难治性高血压的临床有效性和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To determine whether CT-guided ozone-mediated lumbar sympathetic denervation (OL-SDN) displays the clinical efficacy and safety profile in patients with resistant hypertension (RH). |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
患者按预定位置放置在CT台上,监测心率和血压。CT扫描后,确定建议的穿刺位置为椎前神经节,L2上缘水平与腰大肌的前内侧区域和腹主动脉的背外侧相邻,为左肾动脉的起点。测量穿刺深度和角度。2%利多卡因局部麻醉后,21号针头推进至目标点,再次行CT扫描确认。沿针头注入浓度为40 g/ml的13 ml臭氧和氧气的混合物。手术结束后,取出穿刺针。注射后5min第三次CT扫描可见局部臭氧弥散。每5分钟监测1次患者的血压,持续30分钟,然后患者返回医院病房。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
CT-guided ozone-mediated lumbar sympathetic denervation (OL-SDN) The patient is placed on the CT table in a pre-position, and the heart rate and BP are monitored. After a single CT scan (General ElectricsCompany,Hi Speed ZX/i), the proposed needle tip location was determined to be the prevertebral ganglia, adjacent to the anteromedial area of the psoas muscle and the dorsolateral side of the abdominal aorta at the level of the upper edge of L2, where the left kidney artery originates. The depth and angle of the puncture were measured. After local anesthesia with 2% lidocaine, 21 G needles (Japan's Hakko Company) advanced to the target point and were confirmed by another CT scan. After testing the return pump and confirming that it was blood-free and liquid-free, a mixture of 13 ml of ozone and oxygen gas was injected along the needle with a concentration of 40 g/ml. After the procedure, the puncture needle is removed. The diffusion of ozone was observed in the last CT scan five minutes after the injection. The patient's blood pressure was monitored once every five minutes for 30minutes, and he returned to the hospital ward. |
||||||||||||||||||||||
|
纳入标准: |
1.在进行任何评估和治疗之前,必须获得患者书面知情同意。 2.患者男女不限,年龄18 ~ 80岁。 3.根据美国心脏协会的科学声明确诊难治性高血压(RH),即在服用包括一种利尿剂在内的至少三种最大耐受剂量的抗高血压药时,24小时动态血压监测的平均收缩压≥130 mmHg和/或白天时间的平均收缩压≥135 mmHg; 或使用四种或更多的抗高血压药控制血压。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Written informed consent must be obtained before any assessment is performed. |
||||||||||||||||||||||
|
排除标准: |
1.确诊继发性高血压患者(肾动脉狭窄;肾上腺嗜铬细胞瘤;库欣病;原发性醛固酮增多症;阻塞性睡眠呼吸暂停综合征(OSAS))。 2.脊柱畸形、脊柱感染性疾病患者。 3.有肾动脉血管成形术或去神经术史的患者。 4.有腰椎内椎间盘射频消融术和交感神经阻滞史的患者。 5.心肌梗死/脑血管意外(CVA/短暂性脑缺血发作(TIA)病史 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients with confirmed secondary hypertension (all-caused renal artery stenosis; adrenal pheochromocytoma; cushing disease; primary hyperaldosteronism; occluded sleep apnea syndrome (OSAS) ). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-08-01 00:00:00至 To 2023-04-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-08-01 00:00:00 至 To 2022-12-09 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
开放性 |
|
Blinding: |
Open-label |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
ResMan |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF、EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF/EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |